Figure 3.
Progression-free survival with obinutuzumab-chlorambucil versus rituximab-chlorambucil in the CLL11 study. G-Clb = obinutuzumab-chlorambucil, R-Clb = rituximab-chlorambucil. Reprinted from Goede et al36 with permission from the Massachusetts Medical Society.